HomeCompareBNTRF vs ABBV

BNTRF vs ABBV: Dividend Comparison 2026

BNTRF yields 4166.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNTRF wins by $10640008932538.27M in total portfolio value
10 years
BNTRF
BNTRF
● Live price
4166.67%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10640008932538.37M
Annual income
$10,160,323,473,848,406,000.00
Full BNTRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BNTRF vs ABBV

📍 BNTRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNTRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNTRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNTRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNTRF
Annual income on $10K today (after 15% tax)
$354,166.67/yr
After 10yr DRIP, annual income (after tax)
$8,636,274,952,771,145,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BNTRF beats the other by $8,636,274,952,771,123,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNTRF + ABBV for your $10,000?

BNTRF: 50%ABBV: 50%
100% ABBV50/50100% BNTRF
Portfolio after 10yr
$5320004466269.24M
Annual income
$5,080,161,736,924,215,000.00/yr
Blended yield
95.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BNTRF
No analyst data
Altman Z
29.0
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNTRF buys
0
ABBV buys
0
No recent congressional trades found for BNTRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNTRFABBV
Forward yield4166.67%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$10640008932538.37M$102.3K
Annual income after 10y$10,160,323,473,848,406,000.00$24,771.77
Total dividends collected$10607340755579.28M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BNTRF vs ABBV ($10,000, DRIP)

YearBNTRF PortfolioBNTRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$427,367$416,666.67$11,550$430.00+$415.8KBNTRF
2$17,099,286$16,642,004.15$13,472$627.96+$17.09MBNTRF
3$640,595,363$622,299,126.82$15,906$926.08+$640.58MBNTRF
4$22,473,630,166$21,788,193,127.30$19,071$1,382.55+$22473.61MBNTRF
5$738,422,819,738$714,376,035,459.88$23,302$2,095.81+$738422.80MBNTRF
6$22,726,998,462,464$21,936,886,045,344.52$29,150$3,237.93+$22726998.43MBNTRF
7$655,316,167,361,193$630,998,279,006,356.40$37,536$5,121.41+$655316167.32MBNTRF
8$17,705,270,552,284,066$17,004,082,253,207,588.00$50,079$8,338.38+$17705270552.23MBNTRF
9$448,304,166,999,968,600$429,359,527,509,024,600.00$69,753$14,065.80+$448304166999.90MBNTRF
10$10,640,008,932,538,372,000$10,160,323,473,848,406,000.00$102,337$24,771.77+$10640008932538.27MBNTRF

BNTRF vs ABBV: Complete Analysis 2026

BNTRFStock

Benton Resources Inc. operates as a mineral exploration company. It has a diversified property portfolio of gold, silver, nickel, copper, platinum group elements, and lithium assets. The company is advancing projects in Ontario, including flagship Far Lake Copper project located west of Thunder Bay, Ontario, as well as projects, such as the Abernethy, the Armit Lake, the Forester Lake, the Hele, and the Iron Duke projects. It also has strategic alliance with Sokoman Minerals Corp. through three joint-venture properties, including Grey River Gold, Golden Hope, and Kepenkeck in Newfoundland. Benton Resources Inc. was incorporated in 2011 and is headquartered in Thunder Bay, Canada.

Full BNTRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BNTRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNTRF vs SCHDBNTRF vs JEPIBNTRF vs OBNTRF vs KOBNTRF vs MAINBNTRF vs JNJBNTRF vs MRKBNTRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.